ERYTECH announces clinical trial authorizations in Finland and Spain for its European Phase IIb study in AML Post author:admERY Post published:January 15, 2014 Post category:Newsroom ERYTECH announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain. You Might Also Like ERYTECH to Present at Cowen and Company 40th Annual Health Care Conference February 26, 2020 ERYTECH Confirms Plans To Submit BLA for Eryaspase in Hypersensitive ALL Patients July 21, 2021 ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting December 7, 2020
ERYTECH Announces Positive Results from Eryaspase Phase 2 Trial in Acute Lymphoblastic Leukemia Presented at the American Society of Hematology Annual Meeting December 7, 2020